Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07513597 · ClinicalTrials.gov registry record · NA
Assessment of the Effects of a Daily Supplement 4Life Transfer Factor Vista Containing AREDS2 Formula on Skin Carotenoid Levels Using a Non-invasive Detection
A NA study, sponsored by 4Life Research.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT07513597: Completed NA study, sponsored by 4Life Research.
NCT07513597 is a NA study that has completed, run by 4Life Research. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07513597, a NA study, has completed, sponsored by 4Life Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of the clinical study is to evaluate the impact of daily use of a dietary supplement TF Vista containing AREDS2 formula ingredients, astaxanthin (Haematococcus pluvialis) microalgae, bilberry (Vaccinium myrtillus) fruit powder and black currant (Ribes nigrum) fruit powder organic on skin carotenoid levels over an 8-week period for a Cohort 1(n= 20 participants) and 12 weeks for a Cohort 2 (n= 4 participants). Results will be compared using two devices - the Veggie Meter and the Samsung Watch - both of which utilize reflection spectroscopy technology. For Cohort 2 (n = 4 participants), in addition to assessing skin carotenoid levels, the study will also evaluate changes in macular pigment optical density (MPOD) before and after supplementation.
Primary Outcome
Skin carotenoid levels measured via a portable Veggie Meter, Longevity Link Corp. device using reflection spectroscopy on a participant's fingerprint.
Interventions
- OTHER Dietary Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2026-02-14 |
| Phase | NA |
What the finished NCT07513597 record still lists
NCT07513597 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Dietary Supplement is the first listed.
NCT07513597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07513597 about?
NCT07513597 is a clinical study titled "Assessment of the Effects of a Daily Supplement 4Life Transfer Factor Vista Containing AREDS2 Formula on Skin Carotenoid Levels Using a Non-invasive Detection". The goal of the clinical study is to evaluate the impact of daily use of a dietary supplement TF Vista containing AREDS2 formula ingredients, astaxanthin (Haematococcus pluvialis) microalgae, bilberry (Vaccinium myrtillus) fruit powder and black currant (Ribes nigrum) fruit powder organic on skin ca...
What is the current status of trial NCT07513597?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2025-10-16. Estimated completion is 2026-02-14.
What interventions are being tested in trial NCT07513597?
The interventions under investigation include: Dietary Supplement (OTHER).
Who is sponsoring clinical trial NCT07513597?
This trial is sponsored by 4Life Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07513597's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI